CN101168056A - Mixture preparation - Google Patents
Mixture preparation Download PDFInfo
- Publication number
- CN101168056A CN101168056A CNA2006100487554A CN200610048755A CN101168056A CN 101168056 A CN101168056 A CN 101168056A CN A2006100487554 A CNA2006100487554 A CN A2006100487554A CN 200610048755 A CN200610048755 A CN 200610048755A CN 101168056 A CN101168056 A CN 101168056A
- Authority
- CN
- China
- Prior art keywords
- receptor
- crude drug
- agonist
- gaba
- jidingsuan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided is a combinative preparation, belonging to technical field of addiction medicines and neurobiology. The raw materials are receptor agonist raw medicine of ergot dopamine (DA), receptor agonist raw medicine of gamma-propalanine A receptor (GABAA), receptor agonist raw medicine of gamma-propalanine B receptor (GABAB) and excipients. The weight ratios of the raw materials are that the receptor agonist raw medicine of ergot dopamine (DA) is 0.0001% to 30%, the receptor agonist raw medicine of gamma-propalanine A receptor (GABAA) and the receptor agonist raw medicine of gamma- propalanine B receptor (GABAB) are 99.009% to 65%, and the excipients are the rest percentage. Pulvis, drop pills, micro-granules, suppositories, solution type injections, suspension type injections, emulsion type injections, asepsis powder for injection, solutions, syrups, emulsions, suspensions and controlled released preparations are produced by employing the conventional technology. The invention has the advantages of low costs, safety, reliability, little toxic and side effects, obvious shortening of withdrawal time, obvious alleviation or partially relief of psychological drug craving and the like, being adaptable to detoxification medicines for curing various drug addictions.
Description
Technical field:
The present invention relates to a kind of mixture preparation, belong to addiction medicine and neurobiology technical field.
Background technology:
The drug addict that China registers on the books at present surpasses 1,170,000.Drug abuse employee in payroll and 1: 10 ratio of drug addict in the recommendation of drug control organ of the United Nations, China drug addict has broken through 1,100 ten thousand, the existence of this specific group, serious threat is to the social stability and the sustainable development of China, and drug issue has become the main threat that China builds a harmonious society.Want to obtain the triumph of prohibiting drug and fighting drug struggle, must rely on the solution for giving up addiction of drug addict biological medicine technology, the research and development application paces of strengthening this technical field make a breakthrough to banning drugs work and play an important role within a short period of time.
Current, banning drugs work is all paid much attention in countries in the world, and anti-additive medicament is treated as important measures.But, because a series of physiologic derangement phenomenon withdrawal symptoms that the addict is shown when stopping using the opiates medicine suddenly make that they are reluctant to accept drug rehabilitation and the control oneself reverts to take drugs.International drug control organ and academia have been noted that: whether can be smoothly, the physiology drug addiction and the drugs of the genuine withdrawal junkie of people crave for degree, and be that can junkie be accepted to quit drug abuse and prolong the key factor of personal integrity.According to actual in recent years anti-additive medicament research and development of China and applicable cases analysis, though domestic existing anti-additive medicament has kind more than ten, if but these withdrawal and treatment drug mains rely on folk prescription among the people or adding that dependent ingredient is arranged, toxic and side effects is big, lacks scientific basis.The drug rehabilitation quasi drugs of relatively being taken a fancy in the past, treatment principle are " with mild toxicities for big poison ".Lack in the acute detoxification phase under the background of specific drug, methadone helplessly becomes the first-use drug in the current drug addiction treatment, but its dependency is strong, side effect is big, and relapse rate reaches more than 98% after reaching 70%, one year after the January of giving up taking addictive drugs by force.At present China does not also find the ideal physiology that does not contain hyoscyamine, chlorpromazine or do not have the dependence effect to give up or alleviates the medicine that drugs are craved for degree.And in the vigilance addiction or eliminate drugs and crave for and be still blank at present aspect the degree medicine.
Studies have shown that the addict has suffered from disease of brain.Painful main two parts that divide that drugs bring to them, the one, physiology is given up the withdrawal symptoms in the process, this process generally continues 10-15 days, the outbreak of withdrawal symptoms makes junkie very painful, and usually cause their injure himself or make himself disabled behavior, in order to alleviate these miseries, their drugs of reverting to take drugs again; The 2nd, psychological withdrawal, they can't forget that drugs bring their pleasant sensation and lack the possessiveness of quitting drug abuse, and madness is pursued the sort of pleasant sensation at all adventures throughout one's life, and this madness is not can prove effective by education.Prevent to revert to take drugs, shortening or alleviation withdrawal symptoms, elimination simultaneously or reduction addict just become a kind of ideal drug rehabilitation method to the degree of craving for of drugs.
Summary of the invention:
The object of the present invention is to provide a kind of cost low, safe in utilization, scientific strong, reliability height, the mixture preparation that is used for the treatment of drug addiction that toxic and side effects is little.
Principle of the present invention is: medicine can act on different target spots and different neurotransmitteies in the different addiction stages of giving up targetedly, reaches the effect that ideal physiology withdrawal and treatment and auxiliary treatment drugs are craved for degree by acting on opiate system, norepinephrine system, dopamine system, glutamic acid system, corticosterone, GABA system.
Studies show that: the available DA of addict's brain is less than the normal person far away, and its drugs suck the level that has just in time improved DA.Improve level or the exciting DA receptor (D1-D4) of addict's brain DA and don't can produce the direction that new drug dependence is various countries' scientists study always.Ergota class dopamine (DA) receptor stimulating agent can carry out selectivity to the DA system (D1-D4) of brain cortex limbic lobe to be regulated, and improves level or the exciting DA receptor (D1-D4) of addict's brain DA, plays drug treatment function.
Studies show that: γ-An Jidingsuan (GABA) serotonergic neuron of midbrain ventral tegmental area (VTA) can suppress the neuronic transmembrane potential of DA, reduces the release of DA, and drugs and other opioid receptor agonists increase the release of DA just by suppressing the GABA neuron.GABA can suppress the release of DA, has to experimental results show that injecting gaba agonist in the VTA separately can reduce the DA release that drugs cause, and can cause the drugs withdrawal symptom.γ-An Jidingsuan A receptor (GABA
A) agonist or and γ-An Jidingsuan B receptor (GABA
B) agonist can be by to GABA receptor (GABA
AAnd GABA
B) selectivity regulate, control DA discharges, thereby plays the drug rehabilitation effect.
It is also closely related with behavior sensitization to revert to take drugs.Behavior sensitization may be relevant with glutamic acid serotonergic neuron adaptability dysequilibrium with dopaminergic between drug-induced ventral tegmental nucleus, nucleus accumbens septi, frontal cortex, the corpus amygdaloideum.Therefore Ergota class dopamine (DA) receptor stimulating agent, γ-An Jidingsuan A receptor (GABA
A) agonist or and γ-An Jidingsuan B receptor (GABA
B) agonist is by synergism, plays the effect that ideal physiology withdrawal and treatment and auxiliary treatment drugs are craved for degree jointly.
Because drugs infringements, drug addict's physical difference is bigger, therefore selects suitable route of administration, is in time to bring into play drug effect, reduce the drug addict and give up painful effective ways, and we develop different pharmaceutical dosage forms for this reason.
Mixture preparation of the present invention is by Ergota class dopamine (DA) receptor stimulating agent crude drug, γ-An Jidingsuan A receptor (GABA
A) agonist crude drug, γ-An Jidingsuan B receptor (GABA
B) agonist crude drug and adjuvant make powder, drop pill, micropill, suppository, solution type injection agent, suspension type injection, emulsion-type injection, injectable sterile powder, solution, syrup, Emulsion, suspensoid, controlled release agent according to conventional method.Wherein:
The effective ingredient weight ratio of raw material is: Ergota class dopamine (DA) receptor stimulating agent crude drug is 0.001%～30%, γ-An Jidingsuan A receptor (GABA
A) agonist crude drug or γ-An Jidingsuan B receptor (GABA
B) the agonist crude drug is 99.009%～65%, all the other are adjuvant (conventional with).
Ergota class dopamine (DA) receptor stimulating agent crude drug is: bromocriptine methanesulfonate (BromocriptineMesilate), pergolide mesylate (Pergolide Mesylate), lisuride (Lisuride), cabergoline (Cabergoline), alpha-DHEC mesylate (Cripar), Trastal (Trastal) etc.
γ-An Jidingsuan A receptor (GABA
A) the agonist crude drug is: because of ground general grand (indiplon), zolpidem (Zolpidem), gaboxadol (gaboxadol), topiramate (topiramate), Zaleplon (Zaleplon) etc.
γ-An Jidingsuan B receptor (GABA
B) the agonist crude drug is: the derivant of C-34647 Ba (Beclofen), gabapentin (Gabapentin), lyrica (Pregabalin), other γ-An Jidingsuan (as piracetam Piracetam, aniracetam Aniracetam).
Mixture preparation of the present invention is as the application of the anti-additive medicament of treatment drug addiction.
Mixture preparation of the present invention method is routinely carried out animal experiment and has been confirmed its effect, its result of the test unanimity.
Mixture preparation of the present invention shows through animal test results: mixture preparation has very obvious suppression effect to the addiction animal, statistical result showed has significance in 1-5 days after the morphine of stopping using, show that this mixture preparation has the obvious suppression effect to the behavior that morphine class drug dependence causes.
Mixture preparation of the present invention method is routinely carried out the dependency animal experiment, and the result shows no any drug dependence.
Mixture preparation of the present invention has that cost is low, safe, reliable, scientific strong, toxic and side effects is little, can obviously shorten the time of giving up and alleviation or part and remove advantage to the drugs drug craving.
The specific embodiment:
In following examples: adjuvant is starch or dextrin or compound coating material etc.
Embodiment 1:
Select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (Bromocriptine Mesilate) and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug in ground, makes corresponding dosage forms with different consumptions.
A. powder: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 0.001% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 89.999% in ground, adjuvant is 10%, adopts common process to make powder.
Instructions of taking: three times on the one, one time one bag; 5 days is a course of treatment.
B. drop pill: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 1.5% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 97.9% in ground, adjuvant is 0.6%, adopts common process to make drop pill.
Instructions of taking: three times on the one, one time 8; 6 days is a course of treatment.
C. micropill: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 1.5% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 97.9% in ground, adjuvant is 0.6%, adopts common process to make micropill.
Instructions of taking: three times on the one, one time 3 ball, 5 days is a course of treatment.
D. suppository: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 0.002% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 65% in ground, substrate 34.998%, the employing common process is made suppository.
Using method: fill in apart from anus 2cm place, each 1 piece, twice on the one; 6 days is a course of treatment.
E. solution type injection agent: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (Bromocriptine Mesilate) crude drug 11.99% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 88% in ground, additives 0.01% adopt common process to make solution type injection agent.
Using method: every day 10～30mg, intramuscular injection is at twice; Intravenous drip, medicine adds in the 200ml normal saline, drips off in 40 minutes.4 days is a course of treatment.
F. suspension type injection: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (Bromocriptine Mesilate) crude drug 5.0% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 94.85% in ground, additives 0.15% adopt common process to make the suspension type injection.
Using method: intramuscular injection, 20～60mg/ day, divide 2～3 times.5 days is a course of treatment.
J emulsion-type injection: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 14.79% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 83.21% in ground, additives 2.0% adopt common process to make the emulsion-type injection.
Using method: intravenous injection, 20～40mg/ day, once-a-day, 4 days is a course of treatment.
H. injectable sterile powder: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (Bromocriptine Mesilate) crude drug 25.68% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 74.3% in ground, additives 0.2% adopt common process to make injectable sterile powder.
Using method: face and use preceding wiring solution-forming, 10～30mg/ day, intramuscular injection to divide 2 times.Intravenous drip 1 time.4 days is a course of treatment.
I. solution: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 4.8% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 83.2% in ground, additives 12% adopt common process to make solution.
Instructions of taking: three times on the one, one time one, 8 days is a course of treatment.
J syrup: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 0.001% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 65% in ground, syrup 34.999% adopts common process to make syrup.
Instructions of taking: three times on the one, one time one, 8 days is a course of treatment.
K. Emulsion: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 11.65% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 76.35% in ground, emulsifying agent 12% adopts common process to make Emulsion.
Instructions of taking: three times on the one, a 10ml, 7 days is a course of treatment.
L. suspensoid: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 9.95% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 70.05% in ground, additives 20% adopt common process to make suspensoid.
Using method; Face with preceding and be made into debita spissitudo with eliminating cold for resuscitation water, oral, 5g/ day, divide 2 times.5 days is a course of treatment.
M. controlled release agent: select Ergota class dopamine (DA) receptor stimulating agent bromocriptine methanesulfonate (BromocriptineMesilate) crude drug 8.675% and γ-An Jidingsuan A receptor (GABA
A) agonist is because of general grand (indiplon) crude drug 81.625% in ground, adjuvant 11.25% adopts common process to make controlled release agent.
Using method: once-a-day, once two, 5 days is a course of treatment.
Embodiment 2:
Select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (Pergolide Mesylate) and γ-An Jidingsuan B receptor (GABA
B) agonist C-34647 Ba (Beclofen) crude drug, make corresponding dosage forms with different consumption preparation technologies.
A. powder: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (Pergolide Mesylate) crude drug 0.001% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 89.999%, adjuvant is 10%, adopts common process to make powder.
Instructions of taking: three times on the one, one time one bag; 5 days is a course of treatment.
B. drop pill: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 1.5% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 97.9%, adjuvant is 0.6%, adopts common process to make drop pill.
Instructions of taking: three times on the one, one time 8; 6 days is a course of treatment.
C. micropill: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (Pergol ideMesylate) crude drug 1.5% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 97.9%, adjuvant is 0.6%, adopts common process to make micropill.
Instructions of taking: three times on the one, one time 3 ball, 5 days is a course of treatment.
D. suppository: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 0.002% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 65%, substrate 34.998%, adopt common process to make suppository.
Using method: fill in apart from anus 2cm place, each 1 piece, twice on the one; 6 days is a course of treatment.
E. solution type injection agent: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 11.99% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 88%, additives 0.01% adopt common process to make solution type injection agent.
Using method: every day 10～30mg, intramuscular injection is at twice; Intravenous drip, medicine adds in the 200ml normal saline, drips off in 40 minutes.4 days is a course of treatment.
F. suspension type injection: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 5.0% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 94.85%, additives 0.15% adopt common process to make the suspension type injection.
Using method: intramuscular injection, 20～60mg/ day, divide 2～3 times.5 days is a course of treatment.
G. emulsion-type injection: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 14.79% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 83.21%, additives 2.0% adopt common process to make the emulsion-type injection.
Using method: intravenous injection, 20～40mg/ day, once-a-day, 4 days is a course of treatment.
H. injectable sterile powder: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (Pergolide Mesylate) crude drug 25.68% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 74.3%, additives 0.2% adopt common process to make injectable sterile powder.
Using method: face and use preceding wiring solution-forming, 10～30mg/ day, intramuscular injection to divide 2 times.Intravenous drip 1 time.4 days is a course of treatment.
I solution: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 4.8% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 83.2%, additives 12% adopt common process to make solution.
Instructions of taking: three times on the one, one time one, 8 days is a course of treatment.
J syrup: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 0.001% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 65%, syrup 34.999% adopts common process to make syrup.
Instructions of taking: three times on the one, one time one, 8 days is a course of treatment.
K. Emulsion: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 11.65% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 76.35%, emulsifying agent 12% adopts common process to make Emulsion.
Instructions of taking: three times on the one, a 10ml, 7 days is a course of treatment.
L suspensoid: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 9.95% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 70.05%, additives 20% adopt common process to make suspensoid.
Using method; Face with preceding and be made into debita spissitudo with eliminating cold for resuscitation water, oral, 5g/ day, divide 2 times.5 days is a course of treatment.
M. controlled release agent: select Ergota class dopamine (DA) receptor stimulating agent pergolide mesylate (PergolideMesylate) crude drug 8.675% and γ-An Jidingsuan A receptor (GABA
A) agonist C-34647 Ba (Beclofen) crude drug 81.625%, adjuvant 11.25% adopts common process to make controlled release agent.
Using method: once-a-day, once two, 5 days is a course of treatment.
After experimenter person takes 2-5 course of treatment mixture preparation, all can obviously shorten the time of giving up and alleviation or part and remove drug craving, and toxic and side effects is little drugs.
Embodiment 3:
Select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride), γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) and gaboxadol (gaboxadol) crude drug, be prepared into corresponding dosage forms with different consumptions.
A. powder: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 0.001%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 35% and gaboxadol (gaboxadol) crude drug 54.999%, adjuvant is 10%, adopts common process to make powder.
Instructions of taking: three times on the one, one time one bag; 5 days is a course of treatment.
B. drop pill: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 1.5%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 26.325% and gaboxadol (gaboxadol) crude drug 71.575%, adjuvant is 0.6%, adopts common process to make drop pill.
Instructions of taking: three times on the one, one time 8; 6 days is a course of treatment.
C. micropill: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 1.5%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 26.325%, gaboxadol (gaboxadol) crude drug 71.575%, adjuvant is 0.6%, adopts common process to make micropill.
Instructions of taking: three times on the one, one time 3 ball, 5 days is a course of treatment.
D. suppository: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 0.002%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 30% and gaboxadol (gaboxadol) crude drug 35%, substrate 34.998%, adopt common process to make suppository.
Using method: fill in apart from anus 2cm place, each 1 piece, twice on the one; 6 days is a course of treatment.
E. solution type injection agent: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 11.99%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 11.552% and gaboxadol (gaboxadol) crude drug 76.448%, additives 0.01% adopt common process to make solution type injection agent.
Using method: every day 10～30mg, intramuscular injection is at twice; Intravenous drip, medicine adds in the 200ml normal saline, drips off in 40 minutes.4 days is a course of treatment.
F. suspension type injection: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 5.0%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 33.124% and gaboxadol (gaboxadol) crude drug 61.726%, additives 0.15% adopt common process to make the suspension type injection.
Using method: intramuscular injection, 20～60mg/ day, divide 2～3 times.5 days is a course of treatment.
G. emulsion-type injection: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 14.79%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 23.689% and gaboxadol (gaboxadol) crude drug 59.521%, additives 2.0% adopt common process to make the emulsion-type injection.
Using method: intravenous injection, 20～40mg/ day, once-a-day, 4 days is a course of treatment.
H. injectable sterile powder: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 25.68%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 55.68 and gaboxadol (gaboxadol) crude drug 18.62%, additives 0.2% adopt common process to make injectable sterile powder.
Using method: face and use preceding wiring solution-forming, 10～30mg/ day, intramuscular injection to divide 2 times.Intravenous drip 1 time.4 days is a course of treatment.
I. solution: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 4.8%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 65.23%, gaboxadol (gaboxadol) crude drug 17.97%, additives 12% adopt common process to make solution.
Instructions of taking: three times on the one, one time one, 8 days is a course of treatment.
J. syrup: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 0.001%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 13.263% and gaboxadol (gaboxadol) crude drug 51.737%, syrup 34.999% adopts common process to make syrup.
Instructions of taking: three times on the one, one time one, 8 days is a course of treatment.
K Emulsion: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 11.65%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 56.653% and gaboxadol (gaboxadol) crude drug 19.697%, emulsifying agent 12%, adopt common process to make Emulsion.
Instructions of taking: three times on the one, a 10ml, 7 days is a course of treatment.
L. suspensoid: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 9.95%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 36.963% and gaboxadol (gaboxadol) crude drug 33.087%, additives 20% adopt common process to make suspensoid.
Using method; Face with preceding and be made into debita spissitudo with eliminating cold for resuscitation water, oral, 5g/ day, divide 2 times.5 days is a course of treatment.
M. controlled release agent: select Ergota class dopamine (DA) receptor stimulating agent lisuride (Lisuride) crude drug 8.675%, γ-An Jidingsuan A receptor (GABA
A) agonist zolpidem (Zolpidem) crude drug 46.365% and gaboxadol (gaboxadol) crude drug 35.26%, adjuvant 11.25% adopts common process to make controlled release agent.
Using method: once-a-day, once two, 5 days is a course of treatment.
After experimenter person takes 2-5 course of treatment mixture preparation, all can obviously shorten the time of giving up and alleviation or part and remove drug craving, and toxic and side effects is little drugs.
Claims (1)
1. mixture preparation is by Ergota class dopamine (DA) receptor stimulating agent crude drug, γ-An Jidingsuan A receptor (GABA
A) agonist crude drug, γ-An Jidingsuan B receptor (GABA
B) crude drug and the adjuvant of agonist make according to conventional method, it is characterized in that said preparation is powder, drop pill, micropill, suppository, solution type injection agent, suspension type injection, emulsion-type injection, injectable sterile powder, solution, syrup, Emulsion, suspensoid, controlled release agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100487554A CN101168056A (en) | 2006-10-26 | 2006-10-26 | Mixture preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100487554A CN101168056A (en) | 2006-10-26 | 2006-10-26 | Mixture preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101168056A true CN101168056A (en) | 2008-04-30 |
Family
ID=39388909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100487554A Pending CN101168056A (en) | 2006-10-26 | 2006-10-26 | Mixture preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101168056A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112601524A (en) * | 2018-04-06 | 2021-04-02 | 奥维德医疗公司 | Use of gaboxadol for treating substance use disorders |
-
2006
- 2006-10-26 CN CNA2006100487554A patent/CN101168056A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112601524A (en) * | 2018-04-06 | 2021-04-02 | 奥维德医疗公司 | Use of gaboxadol for treating substance use disorders |
| JP2021521103A (en) * | 2018-04-06 | 2021-08-26 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | Use of gaboxadol in the treatment of substance use disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gold | Opiate addiction and the locus coeruleus: the clinical utility of clonidine, naltrexone, methadone, and buprenorphine | |
| Volpicelli | Uncontrollable events and alcohol drinking | |
| Smith | Cocaine-alcohol abuse: Epidemiological, diagnostic and treatment considerations | |
| NO301311B1 (en) | New use of diphenylbutyl-piperazine carboxamides in the treatment of substance abuse disorders | |
| CN101147741A (en) | Medicine for giving up drug | |
| Giannini | An approach to drug abuse, intoxication and withdrawal | |
| CN101168057A (en) | Dopamine agonist preparation | |
| Kruger | Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms | |
| CN101168056A (en) | Mixture preparation | |
| CN101168058A (en) | Mixture preparation | |
| Verma et al. | Role of D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptors in morphine tolerance and dependence in mice | |
| CN1052885C (en) | Chinese medicine herbs for giving off drug of opium | |
| CN101305997B (en) | Medicament for treating nerve dysfunction after refraining opium type material | |
| Sim | Methadone | |
| Eccles | Placebo effects of antitussive treatments on cough associated with acute upper respiratory tract infection | |
| CN1864748A (en) | Preparation of dopamine agonist and application thereof | |
| Singh et al. | Opioid antagonists. I: Pharmacology and rationale for use in treating self-injury | |
| CA2253473A1 (en) | Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
| ISBELL | The newer analgesic drugs; their use and abuse | |
| CN1090026C (en) | Novel medicine for stopping narcotic taking and preparation process thereof | |
| CN1328835A (en) | Medicine preparation for curing abstinence and its application | |
| CN100363006C (en) | Drug addiction-stopping formulation and preparation thereof | |
| CN1298374C (en) | Chinese medicine for giving up drugs | |
| CN110179889B (en) | A Chinese medicinal composition for stopping drug addiction to heroin, and its preparation method | |
| LAL et al. | Effectiveness of nantradol in blocking narcotic withdrawal signs through nonnarcotic mechanisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080430 |